FOLH1 and posterior cortical atrophy: The future focus of study in this unfavorable PCa population must include more accurate staging combined with a smart use of novel systemic agents such as androgen receptor axis targeting drugs, chemotherapy, 177Lu-PSMA theranostics, and stereotactic body radiotherapy in a sandwich therapeutic strategy.